News Breaks |
|
|
| November 12, 2012 |
| 07:30 EDT |  | STJ, VASC, UPI | Barclays to host a bus tour
Medical Supplies & Devices Minneapolis Bus Tour travels throughout the Minneapolis area to visit with various companies on November 12. |
|
|
News For STJ;UPI;VASC From The Last 14 Days Check below for free stories on STJ;UPI;VASC the last two weeks. |
|
|
| May 16, 2013 |
| 16:13 EDT |  | VASC | Vascular Solutions files patent infringement complaint against Boston Scientific
Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. |
|
| 08:05 EDT | | STJ | St. Jude Medical's 3-D vessel reconstruction system approved in Europe
St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform. |
|
| May 14, 2013 |
| 08:09 EDT | | STJ | St. Jude Medical announces first patient enrolled in EnligHTN III study
 Subscribe for More Information |
|
| May 10, 2013 |
| 07:02 EDT | | UPI | Uroplasty announces positive STEP Study 3-year results
Uroplasty highlighted the 3-year results of the STEP Study on percutaneous tibial nerve stimulation treatments for overactive bladder using Uroplasty's Urgent PC Neuromodulation System. Patients who initially responded to 12 weekly Urgent PC treatments were followed for 36 months and received Urgent PC therapy throughout. Patients received an average of 1.1 treatments per month and sustained statistically significant improvements in voiding frequency, urinary urge incontinence episodes, nighttime voids, urgency episodes and voids with moderate to severe urgency, voiding volume and quality of life measures compared to before they began treatment with Urgent PC. There were no serious adverse events reported throughout the study. |
|
| May 9, 2013 |
| 14:01 EDT | | STJ | St. Jude says analysis demonstrates safety, reliability of Optim-insulated leads
Subscribe for More Information |
|
| 09:27 EDT | | STJ | Leerink's medical devices analyst holds a conference call
Subscribe for More Information |
|
| May 8, 2013 |
| 08:09 EDT | | STJ | St. Jude Medical announces CE Mark approval of ICDs, CRT-Ds
Subscribe for More Information |
|
|
|
|
|
